AU602154B2 - Improvements in or relating to organic compounds - Google Patents

Improvements in or relating to organic compounds Download PDF

Info

Publication number
AU602154B2
AU602154B2 AU75587/87A AU7558787A AU602154B2 AU 602154 B2 AU602154 B2 AU 602154B2 AU 75587/87 A AU75587/87 A AU 75587/87A AU 7558787 A AU7558787 A AU 7558787A AU 602154 B2 AU602154 B2 AU 602154B2
Authority
AU
Australia
Prior art keywords
bromocriptine
disease
therapy
day
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU75587/87A
Other languages
English (en)
Other versions
AU7558787A (en
Inventor
Peter Hiestand
Douglas Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU7558787A publication Critical patent/AU7558787A/en
Application granted granted Critical
Publication of AU602154B2 publication Critical patent/AU602154B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU75587/87A 1986-07-14 1987-07-13 Improvements in or relating to organic compounds Ceased AU602154B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14
US885110 1986-07-14

Publications (2)

Publication Number Publication Date
AU7558787A AU7558787A (en) 1988-01-21
AU602154B2 true AU602154B2 (en) 1990-10-04

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75587/87A Ceased AU602154B2 (en) 1986-07-14 1987-07-13 Improvements in or relating to organic compounds

Country Status (13)

Country Link
JP (1) JPS6323817A (enrdf_load_stackoverflow)
KR (1) KR880001292A (enrdf_load_stackoverflow)
AU (1) AU602154B2 (enrdf_load_stackoverflow)
CH (1) CH672987A5 (enrdf_load_stackoverflow)
DE (1) DE3722383A1 (enrdf_load_stackoverflow)
DK (1) DK363887A (enrdf_load_stackoverflow)
FR (1) FR2601245A1 (enrdf_load_stackoverflow)
GB (1) GB2192541B (enrdf_load_stackoverflow)
IT (1) IT1224222B (enrdf_load_stackoverflow)
NL (1) NL8701631A (enrdf_load_stackoverflow)
PH (1) PH24525A (enrdf_load_stackoverflow)
SE (1) SE8702843L (enrdf_load_stackoverflow)
ZA (1) ZA875145B (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US5716932A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
JP5407865B2 (ja) * 2006-11-23 2014-02-05 ジノクサ ファルマ ゲーエムベーハー 毛細管動脈疾患治療用医薬組成物
DK3445362T3 (da) * 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
PL3697418T3 (pl) 2017-10-18 2025-02-03 Veroscience Llc Polepszone preparaty bromokryptyny
CA3149877A1 (en) 2019-09-23 2021-04-01 Anthony H. Cincotta Method for inducing tumor regression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752814A (en) * 1968-05-31 1973-08-14 Sandoz Ltd 2-bromo-alpha-ergocryptine
AU3913685A (en) * 1984-02-29 1985-09-05 Novartis Ag Improvements in or relating to organic compounds
GB2154874A (en) * 1984-02-29 1985-09-18 Sandoz Ltd Bromocriptine compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752814A (en) * 1968-05-31 1973-08-14 Sandoz Ltd 2-bromo-alpha-ergocryptine
AU3913685A (en) * 1984-02-29 1985-09-05 Novartis Ag Improvements in or relating to organic compounds
GB2154874A (en) * 1984-02-29 1985-09-18 Sandoz Ltd Bromocriptine compositions

Also Published As

Publication number Publication date
GB2192541B (en) 1990-05-02
KR880001292A (ko) 1988-04-22
NL8701631A (nl) 1988-02-01
JPS6323817A (ja) 1988-02-01
DK363887D0 (da) 1987-07-13
GB2192541A (en) 1988-01-20
GB8716323D0 (en) 1987-08-19
FR2601245A1 (fr) 1988-01-15
CH672987A5 (enrdf_load_stackoverflow) 1990-01-31
DE3722383A1 (de) 1988-01-28
DK363887A (da) 1988-01-15
IT1224222B (it) 1990-09-26
SE8702843L (sv) 1988-01-15
SE8702843D0 (sv) 1987-07-13
ZA875145B (en) 1989-02-22
PH24525A (en) 1990-07-18
IT8748160A0 (it) 1987-07-10
AU7558787A (en) 1988-01-21

Similar Documents

Publication Publication Date Title
AU602154B2 (en) Improvements in or relating to organic compounds
Inzucchi et al. Type 2 diabetes mellitus
Watkins et al. Diabetes and its management
Mitchell et al. High-dose naltrexone therapy and dietary counseling for obesity
Herold et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
Bacon et al. Penicillamine nephropathy in rheumatoid arthritis: a clinical, pathological and immunological study
Jonas et al. The effect of niacinamide on osteoarthritis: a pilot study
Coutant et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial
Grando New approaches to the treatment of pemphigus
EP0170623A2 (en) Novel pharmaceutical use of (NVA)2-cyclosporine
Beaudry et al. Liver enzyme disturbances during isoniazid chemoprophylaxis in children
Elseviers et al. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use?
Lee et al. Pemphigus foliaceus induced by rifampicin
Steinberg et al. Tryptophan in the treatment of late luteal phase dysphoric disorder: a pilot study
Bock et al. Gastric acidity and gastric biopsy in thyrotoxicosis
Svenningsen et al. Inhibition of insulin release after passive transfer of immunoglobulin from insulin-dependent diabetic children to mice
Jenner et al. Cyclosporin A treatment of young children with newly-diagnosed Type 1 (insulin-dependent) diabetes mellitus
McKendry et al. Clinical experience with DBI (phenformin) in the management of diabetes
Asai et al. Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance
Ni et al. Therapeutic effect of berberine on 60 patients with non-insulin dependent diabetes mellitus and experimental research
Galin et al. Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue
DE10297331T5 (de) Behandlung und Diagnose von Insulin-resistenten Zuständen
Noori et al. Effect of Diabetes Mellitus on Protein–Energy Wasting and Protein Wasting in End‐Stage Renal Disease
Allam et al. Induction of remission in autoimmune polyglandular syndrome type three (APS III): an old drug with new perspectives
Williams et al. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse